Please wait while the formulary information is being retrieved.
Drug overview for MIEBO (PF) (perfluorohexyloctane/pf):
Generic name: perfluorohexyloctane/PF
Drug class:
Therapeutic class: Ophthalmic Agents
Perfluorohexyloctane is an anhydrous semifluorinated alkane.
No enhanced Uses information available for this drug.
Generic name: perfluorohexyloctane/PF
Drug class:
Therapeutic class: Ophthalmic Agents
Perfluorohexyloctane is an anhydrous semifluorinated alkane.
No enhanced Uses information available for this drug.
DRUG IMAGES
No Image Available
The following indications for MIEBO (PF) (perfluorohexyloctane/pf) have been approved by the FDA:
Indications:
Dry eye
Professional Synonyms:
Eye dryness
Xerophthalmia
Indications:
Dry eye
Professional Synonyms:
Eye dryness
Xerophthalmia
The following dosing information is available for MIEBO (PF) (perfluorohexyloctane/pf):
It isessential that the manufacturer's labeling be consulted for more detailed information on dosage and administration of this drug. Dosage summary:
Apply topically to the eye as an ophthalmic solution.
Instill one drop of perfluorohexyloctane four times daily into each eye.
To administer the drug, remove the cap from the eye drop bottle. Hold the bottle upright and gently squeeze the bottle. While squeezing, turn the bottle upside down and release the pressure (drawing air into the bottle).
Keep the bottle upside down, place the bottle above the eye and squeeze it again to release a drop into the eye. Repeat these steps for the second affected eye.
Apply topically to the eye as an ophthalmic solution.
Instill one drop of perfluorohexyloctane four times daily into each eye.
To administer the drug, remove the cap from the eye drop bottle. Hold the bottle upright and gently squeeze the bottle. While squeezing, turn the bottle upside down and release the pressure (drawing air into the bottle).
Keep the bottle upside down, place the bottle above the eye and squeeze it again to release a drop into the eye. Repeat these steps for the second affected eye.
No enhanced Administration information available for this drug.
| DRUG LABEL | DOSING TYPE | DOSING INSTRUCTIONS |
|---|---|---|
| MIEBO 100% EYE DROP | Maintenance | Adults instill 1 drop into affected eye(s) by ophthalmic route 4 times per day |
No generic dosing information available.
The following drug interaction information is available for MIEBO (PF) (perfluorohexyloctane/pf):
There are 0 contraindications.
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for MIEBO (PF) (perfluorohexyloctane/pf):
Drug contraindication overview.
*None.
*None.
There are 0 contraindications.
There are 0 severe contraindications.
There are 0 moderate contraindications.
The following adverse reaction information is available for MIEBO (PF) (perfluorohexyloctane/pf):
Adverse reaction overview.
Most common ocular adverse reaction was blurred vision. Blurred vision was reported in less than 4% of individuals.
Most common ocular adverse reaction was blurred vision. Blurred vision was reported in less than 4% of individuals.
There are 0 severe adverse reactions.
There are 0 less severe adverse reactions.
The following precautions are available for MIEBO (PF) (perfluorohexyloctane/pf):
The safety and effectiveness of perfluorohexyloctane in pediatric patients <18 years have not been established.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
There are no adequate and well controlled studies with perfluorohexyloctane in pregnant women. In animal reproduction studies with oral administration of perfluorohexyloctane during the period of organogenesis, no adverse maternal or developmental effects were observed in rats at doses up to 162 times the recommended human ophthalmic dose (RHOD). Maternal toxicity, miscarriages, and reduced fetal weights were observed in rabbits at all doses tested, with the lowest dose as 41 times the RHOD.
All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies.
All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects is 2 to 4%, and of miscarriage is 15 to 20%, of clinically recognized pregnancies.
There are no data on the presence of perfluorohexyloctane in human milk, the effects on the breastfed infant, or the effects on milk production. The lack of clinical data during lactation precludes a clear determination of the risk of perfluorohexyloctane to an infant during lactation; however, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for perfluorohexyloctane.
No overall differences in safety and effectiveness have been observed between elderly and younger patients.
The following prioritized warning is available for MIEBO (PF) (perfluorohexyloctane/pf):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for MIEBO (PF) (perfluorohexyloctane/pf)'s list of indications:
| Dry eye | |
| H04.12 | Dry eye syndrome |
| H04.121 | Dry eye syndrome of right lacrimal gland |
| H04.122 | Dry eye syndrome of left lacrimal gland |
| H04.123 | Dry eye syndrome of bilateral lacrimal glands |
| H04.129 | Dry eye syndrome of unspecified lacrimal gland |
| H11.14 | Conjunctival xerosis, unspecified |
| H11.141 | Conjunctival xerosis, unspecified, right eye |
| H11.142 | Conjunctival xerosis, unspecified, left eye |
| H11.143 | Conjunctival xerosis, unspecified, bilateral |
| H11.149 | Conjunctival xerosis, unspecified, unspecified eye |
| H16.221 | Keratoconjunctivitis sicca, not specified as sjogren's, right eye |
| H16.222 | Keratoconjunctivitis sicca, not specified as sjogren's, left eye |
| H16.223 | Keratoconjunctivitis sicca, not specified as sjogren's, bilateral |
| H16.229 | Keratoconjunctivitis sicca, not specified as sjogren's, unspecified eye |
Formulary Reference Tool